Forward Therapeutics reports favorable Phase 1 safety and pharmacokinetic data for oral TNFR1 signaling inhibitor FT2109, supporting Phase 2 development.
Written By: Aasritha Thippavajjala, PharmD
Reviewed By: Pharmacally Editorial Team
Forward Therapeutics a Boston-based clinical-stage biotechnology company, announced on October 5, 2026, Phase 1 clinical and preclinical data for FT2109, an oral small molecule designed to selectively inhibit soluble tumor necrosis factor (sTNF)-driven TNFR1 signaling. The clinical data came from a randomized, double-blind, placebo-controlled Phase 1 study in healthy participants. The company said the findings support advancing FT2109 into Phase 2 development.
Phase 1 Study Evaluated FT2109 in Healthy Participants
The first-in-human study enrolled 90 healthy participants and evaluated FT2109 across single ascending dose (SAD) and multiple ascending dose (MAD) cohorts. The SAD portion assessed doses ranging from 2 to 100 mg, while the MAD portion evaluated 15 to 80 mg once daily for 10 days. The study also included food-effect and geriatric cohorts and assessed safety, pharmacokinetics (PK) and pharmacodynamics (PD), including soluble TNF occupancy.
Favorable Safety and Pharmacokinetic Profile
Forward reported a low overall incidence of adverse events that was comparable to placebo. The study recorded no serious adverse events, deaths, dose-limiting toxicities or treatment-emergent adverse events leading to treatment interruption or discontinuation. Reported adverse events were mild or moderate, with no dose-dependent safety trend.
FT2109 demonstrated dose-proportional pharmacokinetics across the evaluated SAD and MAD ranges, with a half-life supporting once-daily oral administration. The drug reached steady state within three to five days. The company also reported comparable PK between geriatric participants and healthy volunteers, while food-effect findings supported administration in either the fed or fasted state.
Because the study was conducted in healthy participants, these findings provide information on safety, tolerability and pharmacology but do not establish clinical efficacy in patients with inflammatory diseases.
Preclinical Data Support Selective TNFR1 Pathway Modulation
FT2109 is designed to selectively inhibit sTNF-driven TNFR1 signaling while preserving membrane TNF-mediated signaling. In preclinical studies, Forward reported high selectivity for sTNF and inhibition of sTNF-mediated TNFR1 signaling, including NF-κB activation and cytotoxicity, while preserving membrane TNF-mediated TNFR1 and TNFR2 signaling.
The compound also demonstrated anti-inflammatory activity in preclinical models. Forward reported reduced cytokine release in an LPS-induced inflammation model and preservation of joint integrity in a collagen-induced arthritis model. In a bacterial challenge model using Listeria monocytogenes, high-dose FT2109 did not produce the infection sensitivity observed with TNF biologic treatment. These findings support the company’s rationale for selectively targeting sTNF while preserving membrane TNF activity.
Development Plans and ACR Convergence Presentations
Forward Therapeutics said the Phase 1 profile provides confidence to advance FT2109 into Phase 2 and pursue development across chronic inflammatory autoimmune diseases, including rheumatoid arthritis. The company has not disclosed detailed Phase 2 study design or timing.
Both the clinical and preclinical datasets have been accepted as abstracts for presentation at the American College of Rheumatology (ACR) Convergence 2026 meeting in Orlando, Florida, from November 6–11.
The Phase 1 study will be presented as Poster 1408 on November 9, while the preclinical work will be presented as Poster 0081 on November 8.
Investigational Status
FT2109 remains an investigational therapy and has not been approved for the treatment of any disease. Forward is developing the oral small molecule as a potential alternative approach to conventional TNF inhibition, citing limitations associated with injectable anti-TNF biologics, including infection risks, demyelinating events, paradoxical inflammatory responses and anti-drug antibodies.
While the Phase 1 findings provide early evidence of favorable safety, tolerability and pharmacologic characteristics, clinical efficacy and the long-term safety profile of FT2109 remain to be established in patients with inflammatory diseases.
Reference
Forward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 Development, Forward Therapeutics, 05 October 2026
About the Writer
Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.